Midostaurin Gets FDA Nod for AML

Cancer Discovery

Abstract

The FDA has approved the small-molecule inhibitor midostaurin in combination with chemotherapy to treat acute myeloid leukemia. It is the first approved drug for the disease that specifically targetsFLT3mutations, which occur in about a quarter of all AML cases and are associated with particularly poor outcomes.

Citations

Dec 30, 2017·Oncotarget·Jennifer N MoloneyThomas G Cotter

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Clinical Advances in Hematology & Oncology : H&O
Jeffrey E Lancet
The New England Journal of Medicine
Richard M StoneHartmut Döhner
The New England Journal of Medicine
Ranjit K Sahoo, Lalit Kumar
© 2022 Meta ULC. All rights reserved